Stephan Sturm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Jes staley says lets get back to the office. Morei think the banks are of a pressing concern, absolute critical. If you think about the advantage that sector needs to make, the changes in diversity, in terms of gender and race, Corporate Culture really important in a bank as well when dealing with risk. All of these things, i can understand why he wants to bring people back into the office. I suspect it is going to be a little more flexible bringing everybody back to the 9to5. Tom Credit Suisse flexible as well. Francine lacqua in zurich. We will get her in the hour. With our first word news i...

Pens last chance to change minds . Away fromf an hour the cache open. What are we looking at question mark lets take a look at the fair value cancellations on the bloomberg create what we are looking at and it want to get these numbers straight, we will skip past this because i have not set this up correctly with the fair value line. Lets talk about what is happening with the gmm. This is what we are looking at, european equities have caught fire. Focus on this column here. The aussie dollar and metal prices have come down. The other movies is british pound story that we are watching carefully...

30 minutes into the trading day in the u. S. Thatmuch awaited data julie hyman is back. Julie in terms of that data, the nonmanufacturing composite index coming in with a reading of 51. 4, that is below the 54. 9 that was estimated. Above 50 is still expansion. The weakest pace in six years. We seen a slowdown in manufacturing as well. Softening in the economic numbers that weve gotten recently. We are seeing stocks hold up relatively well. The nasdaq still hanging onto a gain of. 25 . One thing that may be chipping away at the early gains today come energy prices. We are seeing oil come down ...

Fresenius CEO resigning; to be replaced by head of company’s pharmaceutical business - Michael Sen, President and CEO of Fresenius Kabi, will replace Stephan Sturm as...

Fresenius Kabi's first approved U.S. biosimilar Provides accessible, high-quality treatment option for U.S. cancer patients undergoing chemotherapy to reduce the incidence of infection as